Document is current
Any future updates will be listed below
-
Authors
Riaz, N.
Chen, B. E.
Bane, A.
Gao, D.
Stovgaard, E. S.
Kos, Z.
Leung, S. C.
Shenasa, E.
Parulekar, W.
Chambers, S.
Nielsen, T. O.
Whelan, T. J.
-
Funding
Funding for this research was provided by:
Canadian Cancer Society (705463)
Canadian Breast Cancer Foundation
- License Information
-
More Information
Article History
Received: 4 February 2025
Accepted: 20 August 2025
First Online: 29 August 2025
Competing interests
: T.O.N. reported grants from the Canadian Cancer Society during the conduct of the study; personal fees (PAM50 classifier) from Bioclassifier outside the submitted work; and royalties from Veracyte (holding a patent for the PAM50 classifier). T.J.W. reports in-kind research support from Exact Sciences unrelated to this work. Z.K. has served on paid advisory boards for Eli Lilly, AstraZeneca, and Daiichi Sankyo; and received paid travel expenses from AstraZeneca and Daiichi Sankyo. All other co-authors declare no competing interests.
